Related Experiment Video

Updated: Aug 8, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications

Laura Cerezo1, Higinia Cárdenes, Helen Michael

  • 1Radiation Oncology Service, La Princesa University Hospital, Autonoma University, Madrid, Spain. lcerezo.hlpr@salud.madrid.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|May 2, 2006
PubMed

Insights

Endometrial carcinoma develops through genetic changes specific to Type I and Type II cancers. Identifying these molecular markers aids diagnosis, prognosis, and targeted therapies like transtuzumab and bevacizumab.

Area of Science:

  • Oncology
  • Molecular Genetics
  • Cancer Biology

Background:

  • Endometrial carcinoma development involves sequential oncogene activation and tumor suppressor gene inactivation.
  • Distinct molecular profiles characterize Type I (endometrioid) and Type II (non-endometrioid) endometrial cancers.

Purpose of the Study:

  • To elucidate the specific molecular genetic alterations in Type I and Type II endometrial carcinomas.
  • To explore the clinical utility of molecular markers for diagnosis, prognosis, and targeted therapy development.

Main Methods:

  • Analysis of molecular genetic evidence, including gene mutations (PTEN, KRAS2, TP53, Her-2/neu) and DNA mismatch repair defects (microsatellite instability).
  • Karyotyping to assess ploidy status (diploid vs. non-diploid).

Main Results:

  • Type I cancers show PTEN/KRAS2 mutations, DNA mismatch repair defects, and near-diploid karyotypes.
  • Type II cancers frequently exhibit TP53/Her-2/neu mutations and non-diploid karyotypes.

Conclusions:

  • Molecular alterations are specific to endometrial carcinoma subtypes, offering diagnostic and prognostic value.
  • Tumor biomarkers like Her-2/neu and VEGF are targets for novel therapies such as transtuzumab and bevacizumab.
  • Further research is crucial for identifying new therapeutic targets through molecular and genetic alteration studies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis07:46

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis

Published on: October 13, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...